Insider Trading April 13, 2026 09:52 PM

AEHR Test Systems director sells $745K in stock amid sharp share rally

Director Fariba Danesh disposes 10,500 shares and exercises options as AEHR stock trades near 52-week high

By Priya Menon AEHR
AEHR Test Systems director sells $745K in stock amid sharp share rally
AEHR

Fariba Danesh, a director at AEHR Test Systems, sold 10,500 shares in two transactions in April and exercised 7,000 options the same week. The sales generated roughly $745,588 and leave Danesh with direct ownership of 13,143 shares. The insider moves coincide with a rapid run-up in AEHR stock and mixed quarterly results that include a revenue miss but record bookings and a sizable backlog.

Key Points

  • Insider transaction - Director Fariba Danesh sold 10,500 shares and exercised 7,000 options, leaving direct ownership of 13,143 shares.
  • Valuation and price action - AEHR shares have surged 763% over the past year and 43% in the last week, trading near a 52-week high while InvestingPro's Fair Value estimate sits well below the $71.66 quoted price.
  • Demand indicators - Third-quarter fiscal 2026 results include a modest EPS beat, a slight revenue miss, record quarterly bookings of $37.2 million and an effective backlog above $50 million, prompting mixed analyst reactions.

Fariba Danesh, a director of AEHR Test Systems (NASDAQ: AEHR), completed two stock sales in April that together accounted for 10,500 shares and about $745,588 in proceeds. The first tranche comprised 3,500 shares sold on April 10, 2026, at $70.045 per share; the second tranche was 7,000 shares sold on April 13, 2026, at $71.4901 per share.

On April 13, 2026, Danesh also exercised options to acquire 7,000 shares of AEHR common stock at an exercise price of $2.25 per share, paying $15,750 for the shares obtained through exercise.

After accounting for the sales and the option exercise, Danesh directly holds 13,143 shares of AEHR Test Systems. That total includes shares that remain subject to unvested restricted stock units.

The timing of the insider activity comes against a backdrop of pronounced share-price strength. AEHR has risen 763% over the past year and climbed 43% in the preceding week. The shares were trading near a 52-week high of $74.53 at the time of reporting, with the current quoted price cited at $71.66. InvestingPro analysis referenced in company coverage indicates a Fair Value estimate that is materially below that $71.66 figure, suggesting the stock may be trading above intrinsic valuation.

AEHR carries a market capitalization of $2.22 billion.


Recent financial results and demand indicators

In other corporate developments, AEHR Test Systems reported mixed financial results for the third quarter of fiscal 2026. The company posted an adjusted loss per share of $0.05, which outperformed a consensus forecast of a $0.07 loss per share. Revenue for the quarter was $10.3 million, slightly below the expected $10.8 million figure.

Despite the revenue shortfall, AEHR recorded a company-best level of quarterly bookings at $37.2 million and reported an effective backlog exceeding $50 million, metrics that indicate strong demand for the business's products or services.

Analysts have reacted to the quarter and backlog momentum with varied guidance. Freedom Broker raised its price target to $61 while keeping a Hold rating. Lake Street increased its price target to $56 and retained a Buy rating, citing the strong bookings trend.


Investor resources and valuation tools

For investors seeking further context on valuation and performance, InvestingPro is noted as providing 19 additional ProTips and detailed analysis, including an assessment of whether the stock appears on a Most Overvalued list. The InvestingPro Fair Value calculator is referenced as a tool that aggregates multiple valuation models to derive an estimate.


Key takeaways

  • Insider transactions: Danesh sold 10,500 AEHR shares in two tranches in April and exercised 7,000 options at $2.25 per share on April 13, 2026.
  • Share-price context: AEHR has experienced a 763% rise over 12 months and a 43% increase in the prior week, trading near its 52-week high.
  • Results snapshot: Q3 fiscal 2026 showed an EPS beat amid a slight revenue miss, coupled with record bookings and an effective backlog above $50 million.

Implications for markets

These developments touch both investor sentiment in public markets and demand indicators for the company's products, as reflected in bookings and backlog figures.

Risks

  • Valuation risk - InvestingPro analysis cites a Fair Value estimate significantly below the current price of $71.66, indicating potential overvaluation in the market; this primarily affects equity investors and financial markets.
  • Revenue conversion uncertainty - Revenue for the quarter was $10.3 million versus an expected $10.8 million, highlighting near-term top-line execution risk for AEHR and its suppliers.
  • Reliance on backlog - While bookings reached a record $37.2 million and effective backlog exceeded $50 million, the pace at which backlog converts to revenue remains an uncertainty for operational and supply-chain stakeholders.

More from Insider Trading

ASP Isotopes COO Sells $112.8K in Stock as Company Reports Strong Q4 Revenue Growth Apr 13, 2026 Pitney Bowes EVP Executes $7,969 Stock Sale as Company Reports Mixed Q4 Results and Plans Additional Debt Apr 13, 2026 Jabil Operations Chief Sells $1.2M in Stock as Company Posts Strong Q2 Apr 13, 2026 Photronics Executive Sells $525K in Stock as Company Posts Quarterly Beat and Expands Mask Capacity Apr 13, 2026 Mineralys Chief Medical Officer Disposes of 2,170 Shares, Exercises Equivalent Options Apr 13, 2026